

Agenda 5th AMR Conference 2021 - delivered digitally

Day 1 24 August Status quo & COVID-19 Impact: What has changed after one year of COVID?			
14:00 - 14:45 Opening Session Keynotes	NovaBiotics	Deborah A O'Neil	Chief Executive Officer
	GSK	David Barros-Aguirre	Head of TB Discovery Programme Performance Unit
	BARDA Ventures	Justin Yang	Director, Catalyst Office
	CBE	Janet Hemingway	Director of the Infection Innovation Consortium
14:45 - 15:30 Panel with regulatory bodies	FDA	John Farley	Director, Office of Infectious Diseases (OID)
	EMA	Marco Cavaleri	Head of Biological Health Threats and Vaccines Strategy
15:30 - 16:15 Spotlight on: AMR innovation during the pandemic – challenges and best-practices	JPI AMR	Jessica Boname	Head of Antimicrobial Resistance, Medical Research Council
	AntiResist	Christoph Dehio	Director of NCCR AntiResist
	Infectagnostics Campus	Jürgen Popp	Director of Leibniz Institute of Photonic Technology
	Nosopharm	Philippe Villain-Guillot	Chief Executive Officer and co-founder
Day 2 25 August Financing & Investing: What's new with funds, incubators and accelerators?			
14:00 - 15:00 Infectious diseases in the spotlight – How investors evaluate AMR innovation?	BioVersys	Marc Gitzinger	CEO
	AMR Action Fund	Henry Skinner	CEO
	Novo Repair	Aleks Engel	Partner, Novo Holding
	Acurx Pharmaceuticals	David Luci	President and CEO
15:00 - 16:15 Focus on public-private partnerships in US and Europe – How they drive the AMR pre-clinical pipeline?	Infex Therapeutics	Peter Jackson	
	IMI AMR Accelerator	Anders Karlén	Professor, Uppsala University
	CARB-X	Erin Duffy	Chief of Research & Development
	INCATE	Douglas Häggström	Community Manager INCATE
	AiCuris	Igor Orshanskiy	Director Business Development & Alliance Management
Day 3 26 August Policy & Incentives: What can we learn from best practises to go ahead?			
14:00 - 15:15 What can we expect and learn from the US and UK pull incentive initiatives?	PEW Health Charitable Trust	Kathy Talkington	Director Public Health
	CARB-X	Kevin Outtersen	Executive Director
	NICE	Colm Leonard	Consultant Clinical Adviser
	NHS England	David Glover	Deputy Head of the Medicines Analysis Team
	University of Uppsala	Enrico Baraldi	Professor of Industrial Engineering
	Washington University	Caline Mattar	Assistant Professor of Medicine
15:15 - 16:15 Outlook: How to further drive pull incentives on the policy agenda	WHO	Peter Beyer	Senior Advisor
	IFPMA	Thomas Cueni	Director General
	Paul-Ehrlich-Institut	Isabelle Bekeredjian-Ding	Head of the Microbiology Division
	MSD	Greg Frank	Director Global Public Policy
	Wellcome Trust	Jeremy Knox	Policy and advocacy lead, drug-resistant infections programme
	European Commission	Wolfgang Philipp	Head of Unit, DG Health and Food Security
	Basilea	Mark Jones	